Lion Corporation (4912) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
19 Sep, 2026Overseas business overview and strategy
Achieved strong market positions in Thailand, Malaysia, China, and South Korea, with sales growing 5x in 20 years through advanced technology and localized management.
Unique glocalization strategy combines Japanese technical expertise with deep local adaptation, differentiating from both global and local competitors.
Case studies in China and Hong Kong show success in tailoring products to local preferences, driving significant sales and market share growth.
Oral healthcare market focus and growth drivers
Oral healthcare is prioritized for resource allocation to accelerate sales and profit growth, while beauty care and pharmaceuticals target new high-growth markets.
Asian markets are experiencing rapid population aging and a rise in middle/high-income households, shifting demand toward higher value-added oral care products.
Market growth is driven by rising unit prices and consumer preference for quality and functionality, supported by e-commerce and lifestyle retail channels.
High value-added strategy and localization
Focused investment in high-margin subcategories like whitening, gum care, and sensitive care to avoid price competition and drive profitability.
Localized brand strategies, such as rebranding in Thailand and premiumization in China, are expanding market share and increasing unit prices.
Expansion of distribution channels and rapid product development tailored to local trends are yielding strong initial sales and higher margins.
Latest events from Lion Corporation
- Profits and sales surged, driven by overseas growth and price increases.4912
Q2 2024 - Core operating income surged 47.8% on modest sales growth, led by overseas expansion.4912
Q3 2024 - Profits and sales increased, led by overseas and oral healthcare growth, with higher dividends planned.4912
Q4 2024 - Sales and profits increased year-over-year, driven by overseas growth and higher dividends.4912
Q1 2025 - Core operating income rose 32.3% as overseas expansion and margin gains continued.4912
Q2 2025 - Profits surged on higher value-added sales and Southeast Asia growth; forecasts unchanged.4912
Q3 2025 - 2025 profit and margin growth exceeded targets; 2026 aims for further gains and higher dividends.4912
Q4 2025 - Q1 sales and profit rose 5.3%, led by oral care and overseas gains despite cost headwinds.4912
Q1 2026 - Strong sales and profit growth led by Oral Healthcare and overseas gains, with higher dividend.4912
Q2 2026